New drug combo aims to ease nerve pain in rare blood disorder
NCT ID NCT05939037
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether the drug zanubrutinib, combined with standard rituximab, can improve nerve damage and disability in people with a rare blood condition called IgM MGUS. The study includes 35 adults across two Dutch hospitals. Participants take zanubrutinib daily for at least 6 months, and those who respond well may continue longer. The main goal is to see if walking, arm use, and overall function get better, while also checking for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zanubrutinib (a targeted cancer drug) combined with rituximab (an antibody therapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with nerve damage caused by a rare blood condition, potentially improving mobility and daily function.
- What could go wrong
- This is a small, early-phase trial with only 35 participants and no placebo group. The drug may cause side effects, and results may not apply to all patients. Long-term benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN M MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE RELATED POLYNEUROPATHY WITH MYELIN ASSOCIATED GLYCOPROTEIN ANTIBODIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Medical Center Utrecht
Utrecht, Utrecht, 3584CX, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.